StockIQpro
NASDAQ:CUE

Cue Biopharma, Inc.

Track all markets on TradingView
Track all markets on TradingView

Cue Biopharma, Inc.'s revenue grew 195.7% in fiscal 2025 to $27.5M while operating margin rose to −96.7%, its highest in 8 years. Free cash flow was −$21.9M, −79.6% of revenue, and the diluted share count rose 68.2%.Summary generated from Cue Biopharma, Inc.'s SEC filings. Latest annual report filed Mar 16, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$27.5M
Revenue growth+195.7%
Revenue, 5-yr CAGR+54.2%
Gross marginn/a
Operating margin−96.7%
Net margin−96.9%
ROICn/a
Return on equity−121.1%
Debt / equityn/a
Free cash flow−$21.9M
FCF margin−79.6%
Share count change+68.2%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue1515927
Operating income−44−53−52−42−27
Net income−44−53−51−41−27
Free cash flow−40−42−40−36−22

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations